^
No biomarker
Colon Cancer
capecitabine
Sensitive: A1 - Approval
No biomarker
Colon Cancer
5-fluorouracil + irinotecan
Sensitive: A1 - Approval
No biomarker
Colon Cancer
Mvasi (bevacizumab biosimilar)
Sensitive: A1 - Approval
No biomarker
Colon Cancer
Zirabev (bevacizumab biosimilar)
Resistant: A1 - Approval
No biomarker
Colon Cancer
irinotecan
Sensitive: A1 - Approval
No biomarker
Colon Cancer
Bevax (bevacizumab biosimilar)
Sensitive: A1 - Approval
MSI-H/dMMR
Colon Cancer
CAPOX
Sensitive: A2 - Guideline
MSI-H/dMMR
Colon Cancer
FOLFOX
Sensitive: A2 - Guideline
No biomarker
Colon Cancer
oxaliplatin
Sensitive: A2 - Guideline
No biomarker
Colon Cancer
CAPOX
Sensitive: A2 - Guideline
No biomarker
Colon Cancer
FOLFOX
Sensitive: A2 - Guideline
No biomarker
Colon Cancer
5-fluorouracil + oxaliplatin + leucovorin calcium
Sensitive: A2 - Guideline
No biomarker
Colon Cancer
FLOX
Resistant: A2 - Guideline
No biomarker
Colon Cancer
dostarlimab
Sensitive: A2 - Guideline
No biomarker
Colon Cancer
mFOLFOX6
Sensitive: B - Late Trials
miR-31-5p underexpression
Colon Cancer
cetuximab
Sensitive: B - Late Trials
No biomarker
Colon Cancer
amlodipine/celecoxib
Resistant: B - Late Trials
KRAS G12R
Colon Cancer
cetuximab
Resistant: B - Late Trials
ETV5 overexpression
Colon Cancer
5-fluorouracil
Resistant: B - Late Trials
NTRK3 fusion
Colon Cancer
larotrectinib
Sensitive: C1 - Off-label
NTRK1 fusion
Colon Cancer
larotrectinib
Sensitive: C1 - Off-label
RET fusion
Colon Cancer
pralsetinib
Sensitive: C1 - Off-label
NTRK2 fusion
Colon Cancer
larotrectinib
Sensitive: C1 - Off-label
HER-2 positive
Colon Cancer
ado-trastuzumab emtansine
Sensitive: C1 - Off-label
RET fusion
Colon Cancer
selpercatinib
Sensitive: C1 - Off-label
KRAS G13D
Colon Cancer
cetuximab
Resistant: C2 – Inclusion Criteria
BRAF mutation
Colon Cancer
bevacizumab
Sensitive: C2 – Inclusion Criteria
BRAF V600E
Colon Cancer
cetuximab + vemurafenib
Sensitive: C2 – Inclusion Criteria
ATM mutation
Colon Cancer
Immunotherapy
Sensitive: C3 – Early Trials
BRCA2 mutation
Colon Cancer
Immunotherapy
Sensitive: C3 – Early Trials
ATR mutation
Colon Cancer
Immunotherapy
Sensitive: C3 – Early Trials
RAD50 mutation
Colon Cancer
Immunotherapy
Sensitive: C3 – Early Trials
BRIP1 mutation
Colon Cancer
Immunotherapy
Sensitive: C3 – Early Trials
MAP2K1 K57T
Colon Cancer
cetuximab
Resistant: C3 – Early Trials
SIRT6 underexpression
Colon Cancer
BKM120
Resistant: C3 – Early Trials
FGFR2-INA fusion
Colon Cancer
Debio 1347
Sensitive: C3 – Early Trials
AREG expression
Colon Cancer
cetuximab
Resistant: C3 – Early Trials
FGFR4 expression
Colon Cancer
cetuximab
Resistant: C3 – Early Trials
FGFR2 fusion
Colon Cancer
Debio 1347
Sensitive: C3 – Early Trials
ALK R1209Q
Colon Cancer
crizotinib + pazopanib
Sensitive: C3 – Early Trials
POLE A456P
Colon Cancer
Immunotherapy
Sensitive: C3 – Early Trials
KRAS N116H
Colon Cancer
bevacizumab
Resistant: C4 – Case Studies
KRAS N116T
Colon Cancer
bevacizumab
Resistant: C4 – Case Studies
POLE V411L
Colon Cancer
pembrolizumab
Sensitive: C4 – Case Studies
RAF1 R256S
Colon Cancer
pembrolizumab
Sensitive: C4 – Case Studies
KRAS Q22X
Colon Cancer
panitumumab
Resistant: C4 – Case Studies
MAP2K1 V211D
Colon Cancer
binimetinib
Resistant: C4 – Case Studies
BRAF V600E
Colon Cancer
cetuximab + sorafenib
Sensitive: C4 – Case Studies
PMS2 negative
Colon Cancer
nivolumab + ipilimumab
Sensitive: C4 – Case Studies
TPM3-NTRK1 G595R
Colon Cancer
FCN-098
Sensitive: D – Preclinical
ETV6-NTRK3 G623R
Colon Cancer
FCN-098
Sensitive: D – Preclinical
PIK3CA H1047R
Colon Cancer
PF-05212384
Sensitive: D – Preclinical
KRAS mutation
Colon Cancer
PF-05212384
Sensitive: D – Preclinical
TP53 mutation
Colon Cancer
oxaliplatin
Sensitive: D – Preclinical
SMAD4 mutation
Colon Cancer
oxaliplatin
Sensitive: D – Preclinical
ABCB1 expression
Colon Cancer
eribulin mesylate
Resistant: D – Preclinical
EGFR G719S
Colon Cancer
ABP 494 (cetuximab biosimilar)
Sensitive: D – Preclinical
KRAS G12V
Colon Cancer
CDK9 inhibitor
Sensitive: D – Preclinical
KRAS mutation
Colon Cancer
PF-05212384 + PD-0325901
Sensitive: D – Preclinical
PIK3CA mutation
Colon Cancer
PF-05212384 + PD-0325901
Sensitive: D – Preclinical
KRAS mutation
Colon Cancer
PF-05212384
Sensitive: D – Preclinical
ARID1A deletion
Colon Cancer
talazoparib
Sensitive: D – Preclinical
miR-375 expression
Colon Cancer
cetuximab
Resistant: D – Preclinical
miR-199a-5p expression
Colon Cancer
cetuximab
Resistant: D – Preclinical
MLH1 deletion
Colon Cancer
cetuximab
Resistant: D – Preclinical
PD-L1 expression
Colon Cancer
CCX559
Sensitive: D – Preclinical
TERT mutation + BRAF V600E
Colon Cancer
trametinib + dabrafenib
Sensitive: D – Preclinical
EGFR G724S
Colon Cancer
cetuximab
Sensitive: D – Preclinical
EGFR G719S
Colon Cancer
cetuximab
Sensitive: D – Preclinical
CIC deletion
Colon Cancer
trametinib
Resistant: D – Preclinical
STING mutation
Colon Cancer
CS-1018
Sensitive: D – Preclinical
STING mutation
Colon Cancer
CS-1010
Sensitive: D – Preclinical
STING mutation
Colon Cancer
CS-1020
Sensitive: D – Preclinical
LMNA-NTRK1 G667C
Colon Cancer
FCN-098
Sensitive: D – Preclinical
BRAF V600
Colon Cancer
ABM-1310
Sensitive: D – Preclinical
EGFR E709K
Colon Cancer
panitumumab
Sensitive: D – Preclinical
EGFR G719S
Colon Cancer
panitumumab
Sensitive: D – Preclinical
EGFR L858R
Colon Cancer
panitumumab
Sensitive: D – Preclinical
EGFR L858R
Colon Cancer
cetuximab
Sensitive: D – Preclinical
EGFR E709K
Colon Cancer
cetuximab
Sensitive: D – Preclinical
EGFR P596L
Colon Cancer
panitumumab
Sensitive: D – Preclinical
EGFR R222C
Colon Cancer
panitumumab
Sensitive: D – Preclinical
EGFR R165Q
Colon Cancer
panitumumab
Sensitive: D – Preclinical
EGFR E114K
Colon Cancer
panitumumab
Sensitive: D – Preclinical
EGFR G63R
Colon Cancer
panitumumab
Sensitive: D – Preclinical
EGFR K708R
Colon Cancer
panitumumab
Sensitive: D – Preclinical
EGFR P596L
Colon Cancer
cetuximab
Sensitive: D – Preclinical
EGFR K708R
Colon Cancer
cetuximab
Sensitive: D – Preclinical
EGFR R165Q
Colon Cancer
cetuximab
Sensitive: D – Preclinical
EGFR E114K
Colon Cancer
cetuximab
Sensitive: D – Preclinical
EGFR R222C
Colon Cancer
cetuximab
Sensitive: D – Preclinical
EGFR G63R
Colon Cancer
cetuximab
Sensitive: D – Preclinical